OmniAb (OmniAb) FCF Margin % : -191.37% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is OmniAb FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OmniAb's Free Cash Flow for the three months ended in Dec. 2023 was $-9.23 Mil. OmniAb's Revenue for the three months ended in Dec. 2023 was $4.82 Mil. Therefore, OmniAb's FCF Margin % for the quarter that ended in Dec. 2023 was -191.37%.

As of today, OmniAb's current FCF Yield % is 0.13%.

The historical rank and industry rank for OmniAb's FCF Margin % or its related term are showing as below:

OABI' s FCF Margin % Range Over the Past 10 Years
Min: -35.13 Med: -28.04 Max: 8.02
Current: 2.06

During the past 5 years, the highest FCF Margin % of OmniAb was 8.02%. The lowest was -35.13%. And the median was -28.04%.

OABI's FCF Margin % is ranked better than
81.08% of 1041 companies
in the Biotechnology industry
Industry Median: -143.92 vs OABI: 2.06

OmniAb FCF Margin % Historical Data

The historical data trend for OmniAb's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb FCF Margin % Chart

OmniAb Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-29.75

8.02

-28.04

-35.13

2.06

OmniAb Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial								-34.40	162.27	-155.99	-122.11	-191.37

Competitive Comparison of OmniAb's FCF Margin %

For the Biotechnology subindustry, OmniAb's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OmniAb's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's FCF Margin % distribution charts can be found below:

* The bar in red indicates where OmniAb's FCF Margin % falls into.

OmniAb FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

OmniAb's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	0.703	/	34.164
	=	2.06 %

OmniAb's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-9.228	/	4.822
	=	-191.37 %

OmniAb FCF Margin % Related Terms

Thank you for viewing the detailed overview of OmniAb's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

OmniAb (OmniAb) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608

Website

https://www.omniab.com

OmniAb Inc offers therapeutic antibody discovery technologies. Its focus is to enable the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Executives

Matthew W Foehr	director, officer: President & CEO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Steven Love	director	C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean	director, 10 percent owner	65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Kurt A Gustafson	officer: EVP, Finance and CFO	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Sarah Boyce	director	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010